| Cover - USD ($) $ in Millions | 12 Months Ended | ||
| Dec. 31, 2022 | May 26, 2023 | Jun. 30, 2022 | |
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | NRx Pharmaceuticals, Inc. (the "Company") is filing this Amendment No. 2 (this "Form 10-K/A") to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the Securities and Exchange Commission (the "SEC") on March 31, 2023 (the "Form 10-K"), for the purpose of amending and restating Amendment No. 1 to the Form 10-K, which was filed with the SEC on May 1, 2023 in order to correct certain information on executive compensation provided in Part III, Item 11. As required by Rule 12b-15, in connection with this Form 10-K/A, the Company's Principal Executive Officer and Principal Financial Officer are providing Rule 13a-14(a) certifications included herein. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Because no financial statements are contained within this Form 10-K/A, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Except as explicitly set forth herein, this Form 10-K/A does not purport to modify or update the disclosures in, or exhibits to original Form 10-K, or to update the original Form 10-K to reflect events occurring after the date of such filing. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2022 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2022 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 001-38302 | ||
| Entity Registrant Name | NRX PHARMACEUTICALS, INC. | ||
| Entity Central Index Key | 0001719406 | ||
| Entity Tax Identification Number | 82-2844431 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 1201 Orange Street | ||
| Entity Address, Address Line Two | Suite 600 | ||
| Entity Address, City or Town | Wilmington | ||
| Entity Address, State or Province | DE | ||
| Entity Address, Postal Zip Code | 19801 | ||
| City Area Code | 484 | ||
| Local Phone Number | 254-6134 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 40,584,788.4 | ||
| Entity Common Stock, Shares Outstanding | 70,309,655 | ||
| ICFR Auditor Attestation Flag | false | ||
| Auditor Firm ID | 185 | ||
| Auditor Name | KPMG LLP | ||
| Auditor Location | Short Hills, New Jersey | ||
| Common Stock [Member] | |||
| Title of 12(b) Security | Common Stock, par value $0.001 per share | ||
| Trading Symbol | NRXP | ||
| Security Exchange Name | NASDAQ | ||
| Warrant [Member] | |||
| Title of 12(b) Security | Warrants to purchase one share of Common Stock | ||
| Trading Symbol | NRXPW | ||
| Security Exchange Name | NASDAQ |
